Q1 2023 IMCD NV Earnings Call Transcript
Please go ahead.
Good morning, everyone. As usual, I'm here with Hans Kooijmans and we're happy to take your questions in a moment.
My name is Pieter Slikke. We started 2023 with a strong first quarter with an EBITA growth of 6% and even adjusted for ForEx 8%. Certainly, when you realized that we grew Q1 2022 with 59%, we were able to hold revenue more or less at the same level as quarter 1, 2023, and we're able to increase our margin. The business segments in Life Science performed quite well.
In the industrial segments, we saw effects of destocking and slowing down of demand. We completed 2 acquisitions in Q1, 1 in the U.K. and 1 in China. Sunrise in China will give us a strong position in the beauty and personal care market in that country. We closed a small bolt-on acquisition in Sweden last week, signed 2 deals in South Africa and India, and we expect to do more acquisitions in the course of this year. So we have proven resilience throughout our history. We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |